Information Provided By:
Fly News Breaks for February 27, 2020
Feb 27, 2020 | 09:25 EDT
Roth Capital analyst Yasmeen Rahimi raised the firm's price target on Moderna to $33 from $24 and keeps a Buy rating on the shares. The analyst notes that with its Q4 update, the company continued to emphasize the de-risked nature of mRNA prophylactic vaccines and its strategic focus at making CMV the backbone of Moderna's future.
News For MRNA From the Last 2 Days
Apr 19, 2021 | 12:35 EDT
IBM (IBM) is scheduled to report results of its fiscal first quarter after the market close on April 19, with a conference call scheduled for 5:00 pm ET. What to watch... To see the rest of the story go to See Story Here